Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Max Rosett was appointed as Senior Vice President, Operations at Immunome Inc..
- Action
- appointed
- Role
- Senior Vice President, Operations
Exact text from the filing
Max Rosett 33 Senior Vice President, Operations
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Rapoport resigned as Director at Immunome Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Boylan was appointed as Director at Immunome Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
James Boylan 56 Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Lefenfeld resigned as Director at Immunome Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Philip Wagenheim was appointed as Director at Immunome Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Philip Wagenheim 52 Class III Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Franklyn Prendergast, M.D., Ph.D. was appointed as Director at Immunome Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Franklyn Prendergast, M.D., Ph.D. 78 Class II Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Baron resigned as Director at Immunome Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Corleen Roche was appointed as Chief Financial Officer at Immunome Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
Corleen Roche 57 Chief Financial Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jack Higgins, Ph.D. was appointed as Chief Scientific Officer at Immunome Inc..
- Action
- appointed
- Role
- Chief Scientific Officer
Exact text from the filing
Jack Higgins, Ph.D. 44 Chief Scientific Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandra Stoneman was appointed as Chief Legal Officer and General Counsel at Immunome Inc..
- Action
- appointed
- Role
- Chief Legal Officer and General Counsel
Exact text from the filing
Sandra Stoneman 51 Chief Legal Officer and General Counsel
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Matthew Robinson, Ph.D. was appointed as Chief Discovery Officer, Biology at Immunome Inc..
- Action
- appointed
- Role
- Chief Discovery Officer, Biology
Exact text from the filing
Matthew Robinson, Ph.D. 54 Chief Discovery Officer, Biology
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Clay Siegall, Ph.D. was appointed as Chief Executive Officer, President, Chairman of the Board and Class I Director at Immunome Inc..
- Action
- appointed
- Role
- Chief Executive Officer, President, Chairman of the Board and Class I Director
Exact text from the filing
Clay Siegall, Ph.D. 63 Chief Executive Officer, President, Chairman of the Board and Class I Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Purnanand D. Sarma, Ph.D. resigned as Director and Officer at Immunome Inc..
- Action
- resigned
- Role
- Director and Officer
Exact text from the filing
Purnanand D. Sarma, Ph.D. resigned from Immunome’s board of directors and any respective committee membership of Immunome’s board of directors, and resigned as an officer and employee of Immunome
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Isaac Barchas was appointed as Director at Immunome Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Non-Employee Directors Isaac Barchas 56 Class II Director and Lead Independent Director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dennis Giesing, Ph.D. was terminated as Chief Development Officer at Immunome Inc..
- Action
- terminated
- Role
- Chief Development Officer
Exact text from the filing
Dennis Giesing, Ph.D., Immunome’s former Chief Development Officer, was terminated as an officer and employee of Immunome effective as of the closing of the Merger.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John LaMattina, Ph.D. resigned as Director at Immunome Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bruce Turner, M.D., Ph.D. was appointed as Chief Strategy Officer at Immunome Inc..
- Action
- appointed
- Role
- Chief Strategy Officer
Exact text from the filing
Bruce Turner, M.D., Ph.D. 60 Chief Strategy Officer
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.95
Immunome Inc.: Officer Exculpation Amendment to Immunome's amended and restated certificate of incorporation allowing exculpation of executive officers for certain breaches of fiduciary duty (effective 2023-10-02).
- Change
- charter amendment
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, in connection with the transactions contemplated by the Merger Agreement and following the Special Meeting, Immunome filed certificates of amendment to its Amended and Restated Certificate of Incorporation (the "Immunome Charter") (i) allowing for the exculpation of executive officers for certain breaches of fiduciary duty (the "Officer Exculpation Amendment") and (ii) increasing the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (the "Authorized Share Amendment").
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.95
Immunome Inc.: Authorized Share Amendment to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (effective 2023-10-02).
- Change
- charter amendment
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, in connection with the transactions contemplated by the Merger Agreement and following the Special Meeting, Immunome filed certificates of amendment to its Amended and Restated Certificate of Incorporation (the "Immunome Charter") (i) allowing for the exculpation of executive officers for certain breaches of fiduciary duty (the "Officer Exculpation Amendment") and (ii) increasing the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (the "Authorized Share Amendment").
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Immunome Inc. underwent a change of control involving Morphimmune Inc. (closed 2023-10-02).
- Action
- change of control
- Counterparty
- Morphimmune Inc.
- Closing
- 2023-10-02
Exact text from the filing
On October 2, 2023, Immunome, Merger Sub and Morphimmune consummated the transactions contemplated by the Merger Agreement following a special meeting of Immunome’s stockholders on September 29, 2023 (the “Special Meeting”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Immunome Inc. shareholders approved To approve an amendment to the Immunome 2020 Equity Incentive Plan to increase the total number of shares of Immunome common stock currently available for issuance under the 2020 Plan by 2,955,280 shares at the 2023-09-29 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal 2. To approve an amendment to the Immunome 2020 Equity Incentive Plan to increase the total number of shares of Immunome common stock currently available for issuance under the 2020 Plan by 2,955,280 shares: 6,051,180 For 1,534,559 Against 6,860 Abstain 2,095,419 Broker Non-Votes
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Immunome Inc. shareholders approved To approve an amendment to the Immunome amended and restated certificate of incorporation to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 at the 2023-09-29 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal 4. To approve an amendment to the Immunome amended and restated certificate of incorporation to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000: 9,405,265 For 267,373 Against 15,380 Abstain 0 Broker Non-Votes
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Immunome Inc. shareholders approved To approve a postponement or adjournment of the Immunome special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal at the 2023-09-29 meeting.
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal 5. To approve a postponement or adjournment of the Immunome special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal: 9,399,410 For 279,244 Against 9,364 Abstain 0 Broker Non-Votes
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Immunome Inc. shareholders approved To approve the issuance of shares of Immunome capital stock pursuant to the Merger, which will represent more than 20% of the shares of Immunome common stock outstanding immediately prior to the Merger, pursuant to Rule 5635(a) of the Nasdaq Stock Market LLC (the 'Stock Issuance Proposal') at the 2023-09-29 meeting.
- Proposal
- merger approval
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal 1. To approve the issuance of shares of Immunome capital stock pursuant to the Merger, which will represent more than 20% of the shares of Immunome common stock outstanding immediately prior to the Merger, pursuant to Rule 5635(a) of the Nasdaq Stock Market LLC (the “Stock Issuance Proposal”): 7,564,893 For 26,190 Against 1,516 Abstain 2,095,419 Broker Non-Votes
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Immunome Inc. shareholders approved To approve an amendment to the Immunome amended and restated certificate of incorporation to provide for the exculpation of officers at the 2023-09-29 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-09-29
Exact text from the filing
Proposal 3. To approve an amendment to the Immunome amended and restated certificate of incorporation to provide for the exculpation of officers: 7,472,296 For 108,915 Against 11,388 Abstain 2,095,419 Broker Non-Votes
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.